Ramzi Shaqareq, MD
Pulmonary Disease · St Augustine, FLNPI 1598715229
Payments from drug & device makers
Across 493 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Boehringer Ingelheim$1K
- AstraZeneca$1K
- Takeda Pharmaceuticals U.S.A., Inc.$555
- Insmed, Inc.$332
- Grifols USA, LLC$205
- plus $2K from 30 others
What the payments were for
- Food & beverage$8,15599%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 192 | $2,913 |
| Boehringer Ingelheim | 71 | $1,209 |
| AstraZeneca | 54 | $1,134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $555 |
| Insmed, Inc. | 19 | $332 |
| Grifols USA, LLC | 11 | $205 |
| Genentech USA, Inc. | 18 | $166 |
| Electromed, Inc. | 10 | $156 |
| Regeneron Healthcare Solutions, Inc. | 7 | $156 |
| Pulmonx Corporation | 7 | $150 |
| Harmony Biosciences LLC | 6 | $128 |
| Mylan Specialty L.p. | 5 | $104 |
| Philips North America LLC | 6 | $100 |
| Circassia Inc. | 7 | $96 |
| Mallinckrodt Hospital Products Inc. | 4 | $79 |
| Sunovion Pharmaceuticals Inc. | 4 | $76 |
| Actelion Pharmaceuticals US, Inc. | 3 | $73 |
| United Therapeutics Corporation | 3 | $64 |
| Verona Pharma, Inc. | 3 | $63 |
| Viatris Specialty LLC | 2 | $52 |
| Shire North American Group Inc | 3 | $43 |
| Sanofi | 2 | $43 |
| Inspire Medical Systems, Inc. | 2 | $36 |
| Inogen, Inc. | 2 | $32 |
| Pfizer | 2 | $31 |
| CSL Behring | 2 | $27 |
| 3b Medical, Inc. | 1 | $27 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $23 |
| Merck | 1 | $20 |
| Phadia US Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Vapotherm Inc | 1 | $15 |
| Novartis | 1 | $13 |
| Fisher & Paykel Healthcare Inc | 1 | $12 |
How this compares
$8,205 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 491 | $400,470 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 123 | $74,592 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $33,332 |
| Spiriva RespimatTiotropium Bromide | 38 | $23,444 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $21,745 |
| Incruse ElliptaUmeclidinium Bromide | 33 | $12,720 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $10,493 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $9,729 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 25 | $8,296 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,464 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 253 | $5,929 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $5,361 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $2,726 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,597 |
| Fluticasone Propionate | 26 | $2,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,913 | $512,125723 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,134 | $43,82572 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,209 | $39,63869 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in St Augustine
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.